HER2-pulsed type-1 polarized autologous dendritic cell vaccine

{
  "id": "MLC-T-ONC-014103",
  "term": "HER2-pulsed type-1 polarized autologous dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.",
  "synonyms": [
    "HER2-pulsed DC1 vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/her2-pulsed-type-1-polarized-autologous-dendritic-cell-vaccine/"
}